WO1998032753A1 - THIAZOLE BENZENESULFONAMIDES UTILISES COMME AGONISTES β3 POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE - Google Patents

THIAZOLE BENZENESULFONAMIDES UTILISES COMME AGONISTES β3 POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE Download PDF

Info

Publication number
WO1998032753A1
WO1998032753A1 PCT/US1998/001317 US9801317W WO9832753A1 WO 1998032753 A1 WO1998032753 A1 WO 1998032753A1 US 9801317 W US9801317 W US 9801317W WO 9832753 A1 WO9832753 A1 WO 9832753A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
phenyl
thiazol
amino
benzenesulfonamide
Prior art date
Application number
PCT/US1998/001317
Other languages
English (en)
Inventor
Robert J. Mathvink
Emma R. Parmee
Samuel Tolman
Ann E. Weber
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9705041.3A external-priority patent/GB9705041D0/en
Priority to SK1000-99A priority Critical patent/SK100099A3/sk
Priority to EA199900692A priority patent/EA199900692A1/ru
Priority to AU60384/98A priority patent/AU728812B2/en
Priority to HU0002053A priority patent/HUP0002053A3/hu
Priority to PL98334833A priority patent/PL334833A1/xx
Priority to EP98903677A priority patent/EP0968209A1/fr
Priority to CA002278739A priority patent/CA2278739A1/fr
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to BR9807096-7A priority patent/BR9807096A/pt
Priority to EEP199900328A priority patent/EE9900328A/xx
Priority to JP53214898A priority patent/JP2001509166A/ja
Priority to IL13113098A priority patent/IL131130A0/xx
Publication of WO1998032753A1 publication Critical patent/WO1998032753A1/fr
Priority to IS5131A priority patent/IS5131A/is
Priority to NO993646A priority patent/NO993646L/no
Priority to BG103686A priority patent/BG103686A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Les benzènesulfonamides à substitution thiazole sont des agonistes du récepteur adrénergique β3 présentant une très faible activité de récepteur adrénergique β1 et β2, et en tant que tels, ces composés peuvent accroître la lipolyse et la dépense énergétique dans les cellules. Ces composés sont par conséquent très efficaces dans le traitement du diabète de type II et de l'obésité. Ces composés peuvent également être utilisés pour abaisser les taux de triglycéride et de cholestérol ou augmenter les taux de lipoprotéine haute densité ou diminuer le transit intestinal. En outre, ces composés peuvent être utilisés pour réduire l'inflammation neurogène ou comme antidépresseurs. Ces composés sont préparés par couplage d'un aminoalkylphénylsulfonamide avec un époxyde substitué de façon approprié. L'invention concerne également des composés et des méthodes pour utiliser les composés dans le traitement du diabète et de l'obésité et pour abaisser les taux de triglycéride et de cholestérol ou augmenter les taux de lipoprotéine haute densité ou diminuer le transit intestinal.
PCT/US1998/001317 1997-01-28 1998-01-23 THIAZOLE BENZENESULFONAMIDES UTILISES COMME AGONISTES β3 POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE WO1998032753A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IL13113098A IL131130A0 (en) 1997-01-28 1998-01-23 Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
CA002278739A CA2278739A1 (fr) 1997-01-28 1998-01-23 Thiazole benzenesulfonamides utilises comme agonistes .beta.3 pour le traitement du diabete et de l'obesite
AU60384/98A AU728812B2 (en) 1997-01-28 1998-01-23 Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
HU0002053A HUP0002053A3 (en) 1997-01-28 1998-01-23 Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
BR9807096-7A BR9807096A (pt) 1997-01-28 1998-01-23 Composto, processos para o tratamento do diabetes, da obesidade em um mamìfero, para reduzir nìveis de triglicerìdeos e nìveis de colesterol ou elevar nìveis de lipoproteìnas de alta densidade, para diminuir a motilidade do intestino, para reduzir inflamação neurogênica das vias aéreas e a depressão e para tratar distúrbios gastrintestinais, e, composições para o tratamento dos distúrbios acima e farmacêutica
EP98903677A EP0968209A1 (fr) 1997-01-28 1998-01-23 THIAZOLE BENZENESULFONAMIDES UTILISES COMME AGONISTES $g(b) 3? POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE
EA199900692A EA199900692A1 (ru) 1997-01-28 1998-01-23 БЕНЗОЛСУЛЬФАМИДЫ ТИАЗОЛА КАК βАГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА И ОЖИРЕНИЯ
SK1000-99A SK100099A3 (en) 1997-01-28 1998-01-23 Thiazole benzenesulfonamides as 'beta'3 agonists for the treatment of diabetes and obesity
PL98334833A PL334833A1 (en) 1997-01-28 1998-01-23 Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity
EEP199900328A EE9900328A (et) 1997-01-28 1998-01-23 Tiasooli benseensulfoonamiidid ß3-agonistidena diabeedi ja rasvumuse ravis
JP53214898A JP2001509166A (ja) 1997-01-28 1998-01-23 糖尿病および肥満の治療のためのβ▲下３▼作動薬としてのチアゾールベンゼンスルホンアミド
IS5131A IS5131A (is) 1997-01-28 1999-07-23 Þíazól bensensúlfonamíð sem ß3 gerandefni fyrir meðhöndlun á sykursýki og offitu
NO993646A NO993646L (no) 1997-01-28 1999-07-27 Tiazolbenzensulfonamider som <beta>3-agonister for behandling av diabetes og fedme
BG103686A BG103686A (bg) 1997-01-28 1999-08-24 Тиазолови бензенсулфонамиди като бета3 агонисти за лечението на диабет и затлъстяване

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3676097P 1997-01-28 1997-01-28
US60/036,760 1997-01-28
GB9705041.3 1997-03-12
GBGB9705041.3A GB9705041D0 (en) 1997-03-12 1997-03-12 Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity

Publications (1)

Publication Number Publication Date
WO1998032753A1 true WO1998032753A1 (fr) 1998-07-30

Family

ID=26311166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/001317 WO1998032753A1 (fr) 1997-01-28 1998-01-23 THIAZOLE BENZENESULFONAMIDES UTILISES COMME AGONISTES β3 POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE

Country Status (22)

Country Link
EP (1) EP0968209A1 (fr)
JP (1) JP2001509166A (fr)
KR (1) KR20000070568A (fr)
CN (1) CN1251099A (fr)
AR (1) AR011092A1 (fr)
AU (1) AU728812B2 (fr)
BG (1) BG103686A (fr)
BR (1) BR9807096A (fr)
CA (1) CA2278739A1 (fr)
EA (1) EA199900692A1 (fr)
EE (1) EE9900328A (fr)
HR (1) HRP980044A2 (fr)
HU (1) HUP0002053A3 (fr)
ID (1) ID22273A (fr)
IL (1) IL131130A0 (fr)
IS (1) IS5131A (fr)
NO (1) NO993646L (fr)
PE (1) PE52299A1 (fr)
PL (1) PL334833A1 (fr)
SK (1) SK100099A3 (fr)
TR (1) TR199902442T2 (fr)
WO (1) WO1998032753A1 (fr)

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062892A1 (fr) * 1998-05-29 1999-12-09 Novartis Ag Composes d'aminoazole
WO2001054728A1 (fr) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOUVEAUX REMEDES ET UTILISATION D'UN AGONISTE β3
EP1138685A2 (fr) * 2000-03-31 2001-10-04 Pfizer Products Inc. Procédé de préparation de pyridines substitués
WO2002006221A2 (fr) * 2000-07-17 2002-01-24 Wyeth Sulfonamides cyclylamine en tant qu'agonistes du recepteur adrenergique beta-3
WO2002006276A1 (fr) * 2000-07-13 2002-01-24 Eli Lilly And Company Agonistes adrenergiques beta3
WO2002014312A1 (fr) * 2000-08-15 2002-02-21 F. Hoffmann-La Roche Ag Tétrazolyl-phényl acétamides activateurs de la glucokinase
WO2002046186A1 (fr) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Dérivés thiazole substitués porteurs de groupes 3-pyridyl, procédé d'élaboration et leur utilisation
WO2003000687A1 (fr) * 2001-06-22 2003-01-03 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
WO2003037332A1 (fr) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Heterocycles utiles pour le traitement de l'obesite
US6569873B2 (en) 2000-07-17 2003-05-27 Wyeth Azolidines as beta-3 adrenergic receptor agonists
US6583140B2 (en) 2000-07-17 2003-06-24 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6660752B2 (en) 2001-04-23 2003-12-09 Bayer Pharmaceuticals Corporation 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
US6699860B2 (en) 2000-12-11 2004-03-02 Bayer Pharmaceuticals Corporation Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US6911463B2 (en) 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US7022716B2 (en) 2000-07-17 2006-04-04 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US7071208B2 (en) 2001-11-20 2006-07-04 Eli Lilly And Company β3 Adrenergic agonists
WO2006132196A1 (fr) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation PRODUIT PHARMACEUTIQUE ORIGINAL COMPRENANT UN AGONISTE β3
EP1741446A2 (fr) 2000-01-21 2007-01-10 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
WO2007033266A2 (fr) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
WO2007041052A2 (fr) 2005-09-29 2007-04-12 Merck & Co., Inc. Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4
US7205407B2 (en) 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
US7208505B2 (en) 2001-08-14 2007-04-24 Eli Lilly And Company β3 adrenergic agonists
WO2007044296A3 (fr) * 2005-10-04 2007-09-27 Merck & Co Inc Polytherapie destinee au traitement de la pollakiurie, de la miction imperieuse et de l'incontinence urinaire
WO2008120653A1 (fr) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Dérivé d'indoledione
EP2088154A1 (fr) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles gastro-intestinaux
WO2010047982A1 (fr) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
WO2010051206A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques
EP2305352A1 (fr) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
WO2011069038A2 (fr) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonistes de la guanylate cyclase utiles dans le traitement de l'hypercholestérolémie, de l'athérosclérose, d'une coronaropathie, des calculs biliaires, de l'obésité et d'autres maladies cardiovasculaires
WO2011097079A1 (fr) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase 1 régulant le signal d'apoptose
WO2011106273A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques
WO2012116145A1 (fr) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
WO2013138352A1 (fr) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation
WO2014022528A1 (fr) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
EP2698157A1 (fr) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
WO2014033343A1 (fr) 2012-08-29 2014-03-06 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) Utilisation d'agonistes sélectifs de récepteurs bêta-3 adrénergiques pour le traitement de l'hypertension pulmonaire
WO2014130608A1 (fr) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
EP2810951A2 (fr) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2014197720A2 (fr) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation
WO2015051725A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
EP2998314A1 (fr) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
EP3241839A1 (fr) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2018106518A1 (fr) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
WO2018118670A1 (fr) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
US10288602B2 (en) 2013-01-08 2019-05-14 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatement
US11357757B2 (en) 2017-09-13 2022-06-14 Atrogi Ab Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
US11427539B2 (en) 2017-09-13 2022-08-30 Atrogi Ab Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
US11648216B2 (en) 2017-09-13 2023-05-16 Atrogi Ab Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
US11793774B2 (en) 2017-09-13 2023-10-24 Atrogi Ab Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
WO2023203223A1 (fr) 2022-04-22 2023-10-26 Atrogi Ab Combinaisons d'agonistes du récepteur bêta 2-adrénergique et d'agonistes du récepteur bêta 3-adrénergique et leurs utilisations médicales

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A2 (fr) * 1982-04-08 1983-10-19 Beecham Group Plc Dérivés de l'éthanolamine, procédé pour leur préparation et compositions pharmaceutiques les contenant
EP0611003A1 (fr) * 1993-02-09 1994-08-17 Merck & Co. Inc. Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité
WO1995029159A1 (fr) * 1994-04-26 1995-11-02 Merck & Co., Inc. SULFAMIDES SUBSTITUES UTILISES COMME AGONISTES SELECTIFS VIS-A-VIS DES RECEPTEURS β3-ADRENERGIQUES, POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A2 (fr) * 1982-04-08 1983-10-19 Beecham Group Plc Dérivés de l'éthanolamine, procédé pour leur préparation et compositions pharmaceutiques les contenant
EP0611003A1 (fr) * 1993-02-09 1994-08-17 Merck & Co. Inc. Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité
WO1995029159A1 (fr) * 1994-04-26 1995-11-02 Merck & Co., Inc. SULFAMIDES SUBSTITUES UTILISES COMME AGONISTES SELECTIFS VIS-A-VIS DES RECEPTEURS β3-ADRENERGIQUES, POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062892A1 (fr) * 1998-05-29 1999-12-09 Novartis Ag Composes d'aminoazole
EP1743655A1 (fr) 2000-01-21 2007-01-17 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabétiques
EP1741446A2 (fr) 2000-01-21 2007-01-10 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
WO2001054728A1 (fr) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOUVEAUX REMEDES ET UTILISATION D'UN AGONISTE β3
EP1138685A3 (fr) * 2000-03-31 2003-04-02 Pfizer Products Inc. Procédé de préparation de pyridines substitués
EP1138685A2 (fr) * 2000-03-31 2001-10-04 Pfizer Products Inc. Procédé de préparation de pyridines substitués
US6670480B2 (en) 2000-03-31 2003-12-30 Pfizer Inc. Process for preparing substituted pyridines
US6518431B2 (en) 2000-03-31 2003-02-11 Pfizer Inc. Process for preparing substituted pyridines
US6844441B2 (en) 2000-03-31 2005-01-18 Pfizer Inc Process for preparing substituted pyridines
US6730792B2 (en) 2000-07-13 2004-05-04 Eli Lilly And Company β3 adrenergic agonists
WO2002006276A1 (fr) * 2000-07-13 2002-01-24 Eli Lilly And Company Agonistes adrenergiques beta3
US6649603B2 (en) 2000-07-17 2003-11-18 Wyeth Cyclylamine sulfonamides as β3-adrenergic receptor agonists
US6569873B2 (en) 2000-07-17 2003-05-27 Wyeth Azolidines as beta-3 adrenergic receptor agonists
US6583140B2 (en) 2000-07-17 2003-06-24 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
WO2002006221A3 (fr) * 2000-07-17 2002-06-13 American Home Prod Sulfonamides cyclylamine en tant qu'agonistes du recepteur adrenergique beta-3
US7022716B2 (en) 2000-07-17 2006-04-04 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
WO2002006221A2 (fr) * 2000-07-17 2002-01-24 Wyeth Sulfonamides cyclylamine en tant qu'agonistes du recepteur adrenergique beta-3
US6821991B2 (en) 2000-07-17 2004-11-23 Wyeth 2-substituted thiazolidinones as β-3 adrenergic receptor agonists
WO2002014312A1 (fr) * 2000-08-15 2002-02-21 F. Hoffmann-La Roche Ag Tétrazolyl-phényl acétamides activateurs de la glucokinase
US7122680B2 (en) 2000-11-10 2006-10-17 Eli Lilly And Company 3-Substituted oxindole β3 agonsists
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
WO2002046186A1 (fr) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Dérivés thiazole substitués porteurs de groupes 3-pyridyl, procédé d'élaboration et leur utilisation
US7067537B2 (en) 2000-12-08 2006-06-27 Takeda Pharmaceutical Company Limited Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
US6699860B2 (en) 2000-12-11 2004-03-02 Bayer Pharmaceuticals Corporation Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
US6660752B2 (en) 2001-04-23 2003-12-09 Bayer Pharmaceuticals Corporation 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
US6919371B2 (en) 2001-04-23 2005-07-19 Bayer Pharmaceuticals Corporation 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
WO2003000687A1 (fr) * 2001-06-22 2003-01-03 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
US7208505B2 (en) 2001-08-14 2007-04-24 Eli Lilly And Company β3 adrenergic agonists
US6911463B2 (en) 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
US7087635B2 (en) 2001-08-14 2006-08-08 Eli Lilly And Company 3-substituted oxindole β3 agonists
WO2003037332A1 (fr) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Heterocycles utiles pour le traitement de l'obesite
US7253181B2 (en) 2001-11-20 2007-08-07 Eli Lilly And Company β3 adrenergic agonists
US7205407B2 (en) 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
US7071208B2 (en) 2001-11-20 2006-07-04 Eli Lilly And Company β3 Adrenergic agonists
US7265127B2 (en) 2001-11-20 2007-09-04 Eli Lilly And Company β3 adrenergic agonists
US7241772B2 (en) 2001-11-20 2007-07-10 Eli Lilly And Company β3 adrenergic agonists
US7214697B2 (en) 2002-01-11 2007-05-08 Eli Lilly And Company 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
EP2088154A1 (fr) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles gastro-intestinaux
EP2305352A1 (fr) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
WO2006132196A1 (fr) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation PRODUIT PHARMACEUTIQUE ORIGINAL COMPRENANT UN AGONISTE β3
WO2007033266A2 (fr) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
WO2007041052A2 (fr) 2005-09-29 2007-04-12 Merck & Co., Inc. Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4
US7893091B2 (en) 2005-10-04 2011-02-22 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007044296A3 (fr) * 2005-10-04 2007-09-27 Merck & Co Inc Polytherapie destinee au traitement de la pollakiurie, de la miction imperieuse et de l'incontinence urinaire
EP2698157A1 (fr) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
EP2946778A1 (fr) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de la synthèse d'acides gras
WO2008120653A1 (fr) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Dérivé d'indoledione
EP2998314A1 (fr) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
EP2810951A2 (fr) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839A1 (fr) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2010047982A1 (fr) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
WO2010051206A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
WO2011069038A2 (fr) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonistes de la guanylate cyclase utiles dans le traitement de l'hypercholestérolémie, de l'athérosclérose, d'une coronaropathie, des calculs biliaires, de l'obésité et d'autres maladies cardiovasculaires
EP2923706A1 (fr) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de l'hypercholestérolémie
WO2011097079A1 (fr) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase 1 régulant le signal d'apoptose
WO2011106273A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques
WO2012116145A1 (fr) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
EP3243385A1 (fr) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
EP4309673A2 (fr) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations d'agonistes de guanylate cyclase c et leurs procédés d'utilisation
WO2013138352A1 (fr) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation
EP3708179A1 (fr) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations d'agonistes de guanylate cyclase c et leurs procédés d'utilisation
WO2014022528A1 (fr) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2014033343A1 (fr) 2012-08-29 2014-03-06 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) Utilisation d'agonistes sélectifs de récepteurs bêta-3 adrénergiques pour le traitement de l'hypertension pulmonaire
US10288602B2 (en) 2013-01-08 2019-05-14 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatement
WO2014130608A1 (fr) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
WO2014197720A2 (fr) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation
WO2015051725A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2018106518A1 (fr) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
WO2018118670A1 (fr) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
US11357757B2 (en) 2017-09-13 2022-06-14 Atrogi Ab Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
US11427539B2 (en) 2017-09-13 2022-08-30 Atrogi Ab Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
US11648216B2 (en) 2017-09-13 2023-05-16 Atrogi Ab Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
US11793774B2 (en) 2017-09-13 2023-10-24 Atrogi Ab Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
WO2023203223A1 (fr) 2022-04-22 2023-10-26 Atrogi Ab Combinaisons d'agonistes du récepteur bêta 2-adrénergique et d'agonistes du récepteur bêta 3-adrénergique et leurs utilisations médicales

Also Published As

Publication number Publication date
AU6038498A (en) 1998-08-18
BR9807096A (pt) 2000-04-18
CA2278739A1 (fr) 1998-07-30
HUP0002053A2 (hu) 2001-08-28
CN1251099A (zh) 2000-04-19
EE9900328A (et) 2000-02-15
EA199900692A1 (ru) 2000-02-28
ID22273A (id) 1999-09-23
PE52299A1 (es) 1999-05-26
EP0968209A1 (fr) 2000-01-05
PL334833A1 (en) 2000-03-27
JP2001509166A (ja) 2001-07-10
BG103686A (bg) 2000-06-30
IL131130A0 (en) 2001-01-28
NO993646L (no) 1999-09-27
TR199902442T2 (xx) 2000-07-21
KR20000070568A (ko) 2000-11-25
HRP980044A2 (en) 1998-10-31
HUP0002053A3 (en) 2001-09-28
SK100099A3 (en) 2000-05-16
AU728812B2 (en) 2001-01-18
IS5131A (is) 1999-07-23
NO993646D0 (no) 1999-07-27
AR011092A1 (es) 2000-08-02

Similar Documents

Publication Publication Date Title
AU728812B2 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
US6011048A (en) Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
AU712057B2 (en) Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
US6291491B1 (en) Amide derivatives as β 3 agonists
US5451677A (en) Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5705515A (en) Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
AU717699B2 (en) Chemical compounds
JP3149186B2 (ja) 糖尿病および肥満の治療のための選択的β▲下３▼作用物質としての置換スルホンアミド
JP5290749B2 (ja) ペルオキシソーム増殖剤活性化受容体δの活性化剤
US5541197A (en) Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
RU2501794C2 (ru) Активирующий агент для рецептора, активируемого стимулирующими рост пероксисом агентами
AU4689500A (en) Di-aryl acid derivatives as ppar receptor ligands
WO2009083526A1 (fr) Nouveaux composés
JPWO2002046176A1 (ja) ペルオキシソーム増殖剤応答性受容体の活性化剤
JP2010532748A (ja) カルシウムチャネル遮断薬としての２−置換インドール誘導体
JP2002506033A (ja) ビトロネクチン受容体アンタゴニスト
JP4986927B2 (ja) 医薬
US6034106A (en) Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
JP6937524B2 (ja) アミド化合物およびその使用
CA2521135A1 (fr) Composes heteroaromatiques contenant n en tant que modulateurs de ppars et methodes pour traiter des troubles du metabolisme
US7638540B2 (en) Benzofuran compound and medicinal composition containing the same
US20080207685A1 (en) Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar
US20060217375A1 (en) New compounds
CZ268199A3 (cs) Thiazolbenzensulfonamidy a farmaceutický prostředek
MXPA99007032A (en) THIAZOLE BENZENESULFONAMIDES AS&amp;bgr;3

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131130

Country of ref document: IL

Ref document number: 98803585.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1998 532148

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09341943

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 100099

Country of ref document: SK

Ref document number: 336891

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2278739

Country of ref document: CA

Ref document number: 2278739

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998903677

Country of ref document: EP

Ref document number: P-348/99

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: PV1999-2681

Country of ref document: CZ

Ref document number: PA/a/1999/007032

Country of ref document: MX

Ref document number: 1019997006814

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 60384/98

Country of ref document: AU

Ref document number: 199900692

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1999/02442

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1998903677

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-2681

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1999-2681

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997006814

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 60384/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998903677

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997006814

Country of ref document: KR